ZAP, US. Zomig for appropriate for Primary Care
Study identifier:D1223C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Multicenter, open-label study using the MIDAS questionnaire to assess the effect of using the HCPC guidelines for migraine management in primary care, including the use of Zomig-ZMT (Zolmitriptan) orally disintegrating tablets 5.0mg and Zomig nasal spray 5.0mg as indicated.
Medical condition
migraine
Phase
Phase 4
Healthy volunteers
No
Study drug
Zolmitriptan
Sex
All
Actual Enrollment
120
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Jul 2004
Primary Completion Date: -
Study Completion Date: 01 May 2005
Study design
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Apr 2009 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
